Cover Image
市場調查報告書

報告套組:腫瘤溶解性病毒的免疫療法mRNA疫苗、治療藥

2 Reports Bundle: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

出版商 La Merie Publishing 商品編碼 579795
出版日期 內容資訊 英文
訂單完成後即時交付
價格
Back to Top
報告套組:腫瘤溶解性病毒的免疫療法mRNA疫苗、治療藥 2 Reports Bundle: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics
出版日期: 2017年10月23日 內容資訊: 英文
簡介

本報告套組,提供腫瘤溶解性病毒的免疫療法與mRNA疫苗、治療藥調查分析之系統性資訊。

腫瘤溶解性病毒:開發平台、相關利益者、交易、產業趨勢、機會分析

第1章 摘要整理

第2章 簡介、概要

第3章 腫瘤溶解性病毒的選擇,設計,建立

  • 單純皰疹病毒 (HSV) 類
  • 腺病毒系
  • 牛痘病毒系
  • 水痘性口腔炎病毒 (VSV) 類
  • 新城病病毒 (NDV) 類
  • 其他腫瘤溶解性病毒

第4章 腫瘤溶解性病毒的簡介

  • 單純皰疹病毒 (HSV) 類
  • 腺病毒系
  • 牛痘病毒系
  • 水痘性口腔炎病毒 (VSV) 類
  • 新城病病毒 (NDV) 類
  • 其他腫瘤溶解性病毒
  • 幹細胞遞送腫瘤溶解性病毒

第5章 腫瘤溶解性病毒的開發平台分析

  • 腫瘤溶解性病毒的開發平台概要
  • 核准、已上市的腫瘤溶解性病毒
  • 後期開發階段的腫瘤溶解性病毒
  • 免疫查核點抑制劑、其他抗癌劑和腫瘤溶解性病毒的組合
  • 腫瘤溶解性病毒

第6章 企業簡介

  • 大製藥、生物科技企業
    • Amgen
    • Astellas Pharma
    • AstraZeneca
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene
    • 第一三共
    • Green Cross
    • Jiangsu Hengrui
    • Lee Pharma
    • Medigen Biotechnology
    • Merck
    • 大塚製藥
    • Pfizer
    • Roche
  • 第1代腫瘤溶解性病毒企業
    • Cold Genesys
    • Genelux
    • Latima
    • Multivir/VirRx
    • Neotropix
    • Oncolytics Biotech
    • Shanghai Sunway Biotech
    • SillaJen
    • TaKaRa BIO
    • Theravir
    • Virttu Biologics & TNK Therapeutics
    • Wellstat Biologics
  • 第2代的腫瘤溶解性病毒企業
    • DNAtrix
    • Oncolys BioPharma
    • ORCA Therapeutics
    • Oryx
    • Targovax
    • VCN Biosciences
    • Viralytics
  • 第3代腫瘤溶解性病毒企業
    • Benevir BioPharm
    • Lokon Pharma
    • PsiOxus Therapeutics
    • Transgene
  • 第4代腫瘤溶解性病毒企業
    • Duke University Start-Up Company
    • IGNITE Immunotherapy
    • Oncorus
    • Replimmune
    • TILT Biotherapeutics
    • Turnstone Biologics
    • Unleash Immuno Oncolytics
    • ViraTherapeutics
    • Vyriad
    • Western Oncolytics

第7章 相關利益者分析

第8章 融資、聯盟

第9章 趨勢、機會

第10章 參考資料

mRNA疫苗、治療藥:產業分析 (技術,開發平台,相關利益者,交易)

第1章 摘要整理

第2章 簡介、概要

第3章 mRNA為基礎的疫苗、治療藥的簡介

  • 標準化癌症治療mRNA疫苗
  • 個體化癌症治療mRNA疫苗
  • 感染疾病治療mRNA疫苗
  • 感染疾病預防mRNA疫苗、佐劑
  • 免疫腫瘤學的mRNA
  • 單性疾病的mRNA治療藥
  • 其他疾病的mRNA治療藥

第4章 開發平台分析

  • 標準化癌症治療mRNA疫苗
  • 個體化癌症治療mRNA疫苗
  • 感染疾病治療mRNA疫苗
  • 感染疾病預防mRNA疫苗
  • 染色體的複製RNA感染疾病疫苗等

第5章 主要mRNA、遞送技術的簡介

  • 體外mRNA加載
  • 體內載體、mRNA
  • mRNA疫苗、促效劑/佐劑

第6章 技術分析

第7章 企業簡介

第8章 相關利益者分析

  • mRNA技術企業
  • 有mRNA計劃的製藥公司

第9章 mRNA製造

  • 公司內部
  • 外包

第10章 mRNA的財務預測

第11章 預測

第12章 參考資料

目錄
Product Code: LMFR0024

mRNA is a rather versatile therapeutic modality and offers a range of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

It is increasingly recognized that oncolytic viruses not only are able to directly lyse cancer cells, but they also “free” tumor specific neoantigens, indirectly acting as a cancer vaccine. The so far modest efficacy of oncolytic viruses still can be improved when combined with immune checkpoint inhibitors. This lead to an increased partnering interest of the major immuno-oncology (I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens. Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo.

“Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics” includes the following reports:

  • The Oncolytic Virus Landscape 2017: An Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities
  • mRNA Vaccines & Therapeutics 2017: An Industry Analysis of Technologies, Pipelines, Stakeholders and Deals

Table of Contents

The Oncolytic Virus Landscape 2017: An Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities

1. Executive Summary

2. Introduction & Overview

3. Selection, Design & Construction of Oncolytic Viruses

  • 3.1. Herpes Simplex Virus (HSV) - based Oncolytic Viruses
  • 3.2. Adenoviruses - based Oncolytic Viruses
  • 3.3. Vaccinia Virus - Based Oncolytic Viruses
  • 3.4. Vesicular Stomatitis Virus - based Oncolytic Viruses
  • 3.5. Newcastle Disease Virus - based Oncolytic Viruses
  • 3.6. Various Oncolytic Viruses

4. Profiles of Oncolytic Viruses

  • 4.1. HSV-based Oncolytic Viruses
    • 4.1.1. Imlygic; talimogene laherparepvec; T-Vec; OncoVEX(GM-CSF)
    • 4.1.2. G47Δ
    • 4.1.3. HF10; TB-1401
    • 4.1.4. HSV1716; seprehvir
    • 4.1.5. HSV-Rb-p450
    • 4.1.6. BV-2711
    • 4.1.7. ONCR-001
  • 4.2. Adenovirus-based Oncolytic Viruses
    • 4.2.1. Oncorine
    • 4.2.2. CG0070
    • 4.2.3. DNX-2401
    • 4.2.4. OBP-301; telomelysin
    • 4.2.5. ONCOS-102
    • 4.2.6. Enadenotucirev; ColoAd1
    • 4.2.7. Adenoviral VirRx 007; INGN 007; VRX-007
    • 4.2.8. VCN-01
    • 4.2.9. LOAd703
    • 4.2.10. H103
    • 4.2.11. NG-348
    • 4.2.12. ORCA-010
    • 4.2.13. TILT-123
    • 4.2.14. UIO-112
    • 4.2.15. TILT-324
    • 4.2.16. DNX-2440; Delta-24-RGDOX
    • 4.2.17. DNX-2450
    • 4.2.18. OBP-702
  • 4.3. Vaccinia Virus-based Oncolytic Viruses
    • 4.3.1. Pexastimogene devacirepvec; Pexa-Vec; JX-594; TG6006
    • 4.3.2. GL-ONC1
    • 4.3.3. JX-929; vvDD
    • 4.3.4. TG6002
    • 4.3.5. WO-12
  • 4.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
    • 4.4.1. MG1 Maraba/MAGE-A3(MG1MA3)
    • 4.4.2. VSV-IFNbeta
    • 4.4.3. VSV-IFNbeta-NIS
    • 4.4.4. VSV-GP
  • 4.5. Newcastle Disease Virus-based Oncolytic Viruses
    • 4.5.1. NDV-HUJ
    • 4.5.2. PV701
    • 4.5.3. recNDVGM-CSF
  • 4.6. Various Oncolytic Viruses
    • 4.6.1. Rigvir
    • 4.6.2. Reolysin; pelareorep
    • 4.6.3. CAVATAK; CVA21
    • 4.6.4. MV-NIS
    • 4.6.5. NTX-010; SVV-001
    • 4.6.6. H-1PV
    • 4.6.7. PVS-RIPO
    • 4.6.8. MYX-135
  • 4.7. Stem Cell-delivered Oncolytic Viruses
    • 4.7.1. TBX.OncV (CRad-Survivan-pk7)
    • 4.7.2. MSC-ICOVIR-5

5. Analysis of Oncolytic Virus Pipeline

  • 5.1. Overview of the Pipeline of Oncolytic Viruses
  • 5.2. Approved and Marketed Oncolytic Viruses
  • 5.3. Late Stage Development of Oncolytic Viruses
  • 5.4. Combination of Oncolytic Viruses with Immune Checkpoint Inhibitors and Other Anti-Tumor Agents
  • 5.5. Armed Oncolytic Viruses

6. Company Profiles

  • 6.1. Pharma & Biotech
    • 6.1.1. Amgen
    • 6.1.2. Astellas Pharma
    • 6.1.3. AstraZeneca
    • 6.1.4. Boehringer Ingelheim
    • 6.1.5. Bristol-Myers Squibb
    • 6.1.6. Celgene
    • 6.1.7. Daiichi Sankyo
    • 6.1.8. Green Cross
    • 6.1.9. Jiangsu Hengrui
    • 6.1.10. Lee Pharma
    • 6.1.11. Medigen Biotechnology
    • 6.1.12. Merck
    • 6.1.13. Otsuka Pharmaceutical Co
    • 6.1.14. Pfizer
    • 6.1.15. Roche
  • 6.2. First Generation Oncolytic Virus Companies
    • 6.2.1. Cold Genesys
    • 6.2.2. Genelux
    • 6.2.3. Latima
    • 6.2.4. Multivir / VirRx
    • 6.2.5. Neotropix
    • 6.2.6. Oncolytics Biotech
    • 6.2.7. Shanghai Sunway Biotech
    • 6.2.8. SillaJen
    • 6.2.9. Takara Bio
    • 6.2.10. Theravir
    • 6.2.11. Virttu Biologics & TNK Therapeutics
    • 6.2.12. Wellstat Biologics
  • 6.3. Second Generation Oncolytic Virus Companies
    • 6.3.1. DNAtrix
    • 6.3.2. Oncolys BioPharma
    • 6.3.3. ORCA Therapeutics
    • 6.3.4. Oryx
    • 6.3.5. Targovax
    • 6.3.6. VCN Biosciences
    • 6.3.7. Viralytics
  • 6.4. Third Generation Oncolytic Virus Companies
    • 6.4.1. Benevir BioPharm
    • 6.4.2. Lokon Pharma
    • 6.4.3. PsiOxus Therapeutics
    • 6.4.4. Transgene
  • 6.5. Fourth Generation Oncolytic Virus Companies
    • 6.5.1. Duke University Start-Up Company
    • 6.5.2. IGNITE Immunotherapy
    • 6.5.3. Oncorus
    • 6.5.4. Replimmune
    • 6.5.5. TILT Biotherapeutics
    • 6.5.6. Turnstone Biologics
    • 6.5.7. Unleash Immuno Oncolytics
    • 6.5.8. ViraTherapeutics
    • 6.5.9. Vyriad
    • 6.5.10. Western Oncolytics

7. Stakeholder Analysis

  • 7.1. Pharma & Biotech
  • 7.2. First Generation Oncolytic Virus Companies
  • 7.3. Second Generation Oncolytic Virus Companies
  • 7.4. Third Generation Oncolytic Virus Companies
  • 7.5. Fourth Generation Oncolytic Virus Companies

8. Financing & Partnering

  • 8.1. Grants, Credits & Donations
  • 8.2. Venture Capital, Private Equity & Private Placements
  • 8.3. Partnering Deals
  • 8.4. Listing on the Stock Market
  • 8.5. Mergers & Acquisitions

9. Trends & Opportunities

10. References

Tables in the Text:

  • Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses
  • Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses
  • Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses
  • Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses
  • Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses
  • Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses
  • Table 7: Current Company-Sponsored Clinical Trials of T-Vec
  • Table 8: Clinical Trials of ColoAd1
  • Table 9: Clinical Trials with JX-594
  • Table 10: Clinical Trials with GL-ONC1
  • Table 11: Clinical Trials of CAVATAK (CVA21)
  • Table 12: Clinical Trials with MV-NIS
  • Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family
  • Table 14: Profile of Approved and Marketed Oncolytic Viruses
  • Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results
  • Table 16: Approved Indications of Immune Checkpoint Inhibitors
  • Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
  • Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
  • Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics
  • Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase
  • Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and/or Positive Completed Clinical Studies
  • Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses
  • Table 23: Immuno-Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses
  • Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses
  • Table 25: First Generation Oncology Virus Companies and their Sources of Technology
  • Table 26: Second Generation Oncology Virus Companies and their Sources of Technology
  • Table 27: Third Generation Oncology Virus Companies and their Sources of Technology
  • Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology
  • Table 29: Grants, Credits & Donations
  • Table 30: Financing by Venture Capital, Private Equity and Other Private Placements
  • Table 31: Collaboration & Licensing Agreements
  • Table 32: Companies Listed on Stock Exchange & Offerings
  • Table 33: Mergers & Acquisitions

Companies mentioned in the report:

  • Amgen
  • Astellas Pharma
  • AstraZeneca (MedImmune)
  • Bayer
  • Benevir Biopharm
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Cold Genesys
  • Daiichi Sankyo
  • DNAtrix
  • Duke University start-up Company
  • GeneLux
  • Green Cross
  • Grifols
  • GSK (GlaxoSmithKline)
  • IGNITE Immunotherapy
  • Jiangsu Hengrui
  • Latima
  • Lee's Pharma
  • Lokon Pharma
  • Medigen Biotechnology
  • Merck
  • Multivir
  • Neotropix
  • Oncolys BioPharma
  • Oncolytics Biotech
  • Oncorus
  • Orca Therapeutics
  • Oryx
  • Otsuka Pharmaceutical Co
  • Pfizer
  • Profectus Biosciences
  • PsiOxus
  • Replimune
  • Roche
  • Shanghai Sunway Biotech
  • SillaJen
  • Sotio
  • StemImmune
  • StingInn
  • Takara Bio
  • Targovax
  • TheraBiologics
  • Theravir
  • TILT Biotherapeutics
  • Transgene
  • Turnstone Biologics
  • Unleash Immuno Oncolytics
  • VCN Biosciences
  • Viralytics
  • ViraTherapeutics
  • Virttu Biologics (TNK Therapeutics)
  • Vyriad
  • Wellstat Biologics
  • Western Oncolytics

mRNA Vaccines & Therapeutics 2017: An Industry Analysis of Technologies, Pipelines, Stakeholders and Deals

1. Executive Summary

2. Introduction & Overview

3. Profiles of mRNA-based Vaccines & Therapeutics

  • 3.1. Standardized Therapeutic Cancer mRNA Vaccines
    • 3.1.1. BI-1361849; CV9202 & CV9201
    • 3.1.2. CV9104 & CV9103
    • 3.1.3. Tetravalent Lipo-MERIT Vaccine
    • 3.1.4. TriMixDC-Mel
  • 3.2. Individualized Therapeutic Cancer mRNA Vaccines
    • 3.2.1. IVAC Mutanome
    • 3.2.2. IVAC Warehouse
    • 3.2.3. mRNA-4157
    • 3.2.4. Rocapuldencel-T; AGS-003
  • 3.3. Therapeutic Infectious Disease mRNA Vaccines
    • 3.3.1. AGS-004
  • 3.4. Prophylactic Infectious Disease mRNA Vaccines & Adjuvants
    • 3.4.1. CV7201
    • 3.4.2. MRK-1777
    • 3.4.3. mRNA-1325
    • 3.4.4. mRNA-1388
    • 3.4.5. mRNA-1440; VAL-506440
    • 3.4.6. mRNA-1647
    • 3.4.7. mRNA-1653
    • 3.4.8. mRNA-1706
    • 3.4.9. mRNA-1851; VAL-339851
    • 3.4.10. RNAdjuvant; CV8102
  • 3.5. mRNA in Immuno-Oncology
    • 3.5.1. CARMA-hMeso
    • 3.5.2. CTX101
    • 3.5.3. mRNA-2416
    • 3.5.4. mRNA-2905
  • 3.6. mRNA Therapeutic for Monogenetic Diseases
    • 3.6.1. CRISPR/Cas9 TTR mRNA-LNP
    • 3.6.2. PRX-ASL
    • 3.6.3. PRX-ASS1
    • 3.6.4. PRX-OTC
  • 3.7. mRNA Therapeutic for Other Diseases
    • 3.7.1. AZD8601

4. Pipeline Analysis

  • 4.1. Standardized mRNA Cancer Vaccines
  • 4.2. Individualized mRNA Cancer Vaccines
  • 4.3. Therapeutic mRNA Infectious Disease Vaccines
  • 4.4. Prophylactic mRNA Infectious Disease Vaccines
  • 4.5. Replicon RNA Infectious Disease Vaccines
  • 4.6. mRNA Protein Therapeutics for Cancer and Cardiovascular Diseases
  • 4.7. mRNA Protein Therapeutics for Ornithine TransCarbomylase (OTC) Deficiency
  • 4.8. mRNA Protein Therapeutics for Cystic Fibrosis
  • 4.9. mRNA Protein Therapeutics for Other Genetic Diseases
  • 4.10. mRNA Antibody Therapeutics
  • 4.11. Therapeutic mRNA-based Gene Editing
  • 4.12. Ex vivo mRNA-based T-Cell Engineering

5. Profiles of Selected mRNA & Delivery Technologies

  • 5.1. Ex vivo mRNA Loading
    • 5.1.1. Arcelis Technology
    • 5.1.2. Flow Electroporation Technology
  • 5.2. In vivo Carrier & mRNA
    • 5.2.1. Hybrid mRNA Technology
    • 5.2.2. Lipid Nanoparticle (LNP) mRNA Technology
    • 5.2.3. Nanotaxi Technology
    • 5.2.4. RNArt & RNAntibody Technology
    • 5.2.5. UNA & LUNAR Technologies
  • 5.3. mRNA Vaccines & Stimulants / Adjuvants
    • 5.3.1. RNActive Technology
    • 5.3.2. Self-Amplifying mRNA (SAM) Technology
    • 5.3.3. TriMix Technology

6. Technology Analysis

  • 6.1. mRNA Modifications
  • 6.2. mRNA Efficiencies
  • 6.3. Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines
  • 6.4. Carriers for mRNA-based Protein & Antibody Therapeutics

7. Company Profiles

  • 7.1. Companies focused on mRNA Therapeutics and Vaccines
    • 7.1.1. Arcturus Therapeutics
    • 7.1.2. Argos Therapeutics
    • 7.1.3. BioNTech
    • 7.1.4. CureVac
    • 7.1.5. eTheRNA immunotherapies
    • 7.1.6. Ethris
    • 7.1.7. In-Cell-Art
    • 7.1.8. Kernal Biologics
    • 7.1.9. Moderna Therapeutics
    • 7.1.10. PhaseRx
    • 7.1.11. RaNa Therapeutics
  • 7.2. Companies with a focus on self-amplifying mRNA (Replicon RNA)
    • 7.2.1. GlaxoSmithKline Vaccines
    • 7.2.2. Synthetic Genomics
    • 7.2.3. Tiba Biotechnology
  • 7.3. Companies with a focus on mRNA Delivery
    • 7.3.1. Acuitas Therapeutics
    • 7.3.2. Arbutus Biopharma
    • 7.3.3. Silence Therapeutics
  • 7.4. Companies with a focus on Gene Editing and CAR T-Cells
    • 7.4.1. CRISPR Therapeutics & Casebia Therapeutics
    • 7.4.2. Intellia Therapeutics
    • 7.4.3. MaxCyte
    • 7.4.4. Sangamo Therapeutics
    • 7.4.5. ZIOPHARM Oncology
  • 7.5. Companies focused on Contract Manufacturing of mRNA
    • 7.5.1. TriLink BioTechnologies
    • 7.5.2. Precision NanoSystems
  • 7.6. Biopharmaceutical Companies with mRNA Programs
    • 7.6.1. Alexion Pharmaceuticals
    • 7.6.2. Regeneron Pharmaceuticals
    • 7.6.3. Ultragenyx Pharmaceutical
    • 7.6.4. Vertex Pharmaceuticals
  • 7.7. Major Pharmaceutical Companies with mRNA Programs
    • 7.7.1. AstraZeneca
    • 7.7.2. Bayer
    • 7.7.3. Boehringer Ingelheim
    • 7.7.4. Janssen
    • 7.7.5. Merck
    • 7.7.6. Roche
    • 7.7.7. Sanofi
    • 7.7.8. Takeda Pharmaceutical Co.

8. Stakeholder Analysis

  • 8.1. mRNA Technology Companies
    • 8.1.1. Companies Focused on mRNA Vaccines & Therapeutics
    • 8.1.2. Companies Focused on Self-Amplifying mRNA
    • 8.1.3. Companies Focused on mRNA Delivery
    • 8.1.4. Companies Focused on Gene Editing & CAR T-Cells by Use of mRNA
  • 8.2. Pharmaceutical Companies with mRNA Programs
    • 8.2.1. Rare Disease Biopharmaceutical Companies with mRNA Programs
    • 8.2.2. Major Pharmaceutial Companies with mRNA Programs

9. mRNA Manufacturing

  • 9.1. In-house mRNA Manufacturing
  • 9.2. Out-sourced mRNA Manufacturing

10. Financial Perspective on mRNA

  • 10.1. mRNA Partnering Deals
  • 10.2. Funded mRNA Programs

11. Outlook

12. References

List of Tables:

  • Table 1: mRNA Modalities and Number of Programs per R&D Phase
  • Table 2: Pipeline of Standardized mRNA Cancer Vaccines
  • Table 3: Pipeline of Individualized mRNA Cancer Vaccines
  • Table 4: Pipeline of Therapeutic mRNA Infectious Disease Vaccines
  • Table 5: Pipeline of Prophylactic mRNA Infectious Disease Vaccines
  • Table 6: Pipeline of Replicon RNA Infectious Disease Vaccines
  • Table 7: Pipeline of mRNA Protein Therapeutics for Cancer and CV Diseases
  • Table 8: Pipeline of mRNA Therapeutics for OTC Deficiency
  • Table 9: Pipeline of mRNA Therapeutics for Cystic Fibrosis
  • Table 10: Pipeline of mRNA Protein Therapeutics for Other Genetic Diseases
  • Table 11: Pipeline of mRNA Antibody Therapeutics
  • Table 12: Pipeline of mRNA for ex vivo Gene Editing
  • Table 13: Pipeline of mRNA for in vivo Gene Editing
  • Table 14: Pipeline of mRNA for ex vivo T-Cell Engineering
  • Table 15: Examples of mRNA Modifications
  • Table 16: Efficiency of mRNA +/- Carrier in Preclinical Models
  • Table 17: Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines
  • Table 18: Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines
  • Table 19: mRNA Therapeutics Pipeline of Arcturus Therapeutics
  • Table 20: BioNTech's Pipeline of mRNA-based Vaccines & Therapeutics
  • Table 21: CureVac's Pipeline of mRNA-Based Vaccines and Therapeutics
  • Table 22: Moderna's R&D Pipeline of Infectious Disease mRNA Vaccines
  • Table 23: Moderna Therapeutics R&D Pipeline in Immuno-Oncology
  • Table 24: Moderna Therapeutics R&D Pipeline of mRNA Therapeutics
  • Table 25: Ex vivo Gene Editing Programs of CRISPR Therapeutics
  • Table 26: In vivo Gene Editing Programs of CRISPR Therapeutics
  • Table 27: Alexion Pharmaceuticals' mRNA Therapeutics Pipeline
  • Table 28: mRNA-based R&D Programs of Vertex Pharmaceuticals
  • Table 29: Summary Profiles of mRNA Vaccines & Therapeutics Companies
  • Table 30: R&D Focus of Major mRNA Players
  • Table 31: Technology Profiles of Small mRNA Therapeutics Companies
  • Table 32: mRNA Companies as Participants in Consortium R&D
  • Table 33: Biopharmaceutical Companies and Partnered mRNA Programs
  • Table 34: Big Pharma Companies and Partnered mRNA Programs
  • Table 35: mRNA Companies and Manufacturing Solutions
  • Table 36: Financial Terms of Partnering Deals with mRNA Companies
  • Table 37: Funded mRNA Vaccines & Therapeutics Programs

Companies mentioned in the report:

  • Acuitas Therapeutics
  • Alexion Pharmaceuticals
  • Arbutus Biopharma
  • Arcturus Therapeutics
  • Argos Therapeutics
  • AstraZeneca
  • Bayer
  • BioNTech
  • Boehringer Ingelheim
  • CRISPR Therapeutics
  • CureVac
  • eTheRNA immunotherapies
  • Ethris
  • GlaxoSmithKline Vaccines
  • In-Cell-Art
  • Intellia Therapeutics
  • Janssen
  • Kernal Biologics
  • MaxCyte
  • Moderna Therapeutics
  • Novartis
  • PhaseRx
  • Precision NanoSystems
  • RaNa Therapeutics
  • Regeneron Pharmaceuticals
  • Roche
  • Sangamo Therapeutics
  • Sanofi
  • Siemens
  • Silence Therapeutics
  • Synthetic Genomics
  • Takeda Pharmaceutical Co
  • Tiba Biotechnology
  • TriLink BioTechnologies
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • ZIOPHARM Oncology
Back to Top